Flexion Therapeutics, Inc. (NASDAQ:FLXN) had its price objective boosted by Needham & Company LLC from $36.00 to $42.00 in a research note released on Monday, MarketBeat Ratings reports. Needham & Company LLC currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on the company. Wells Fargo & Company set a $39.00 target price on Flexion Therapeutics and gave the company a buy rating in a research note on Friday, October 6th. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the company a buy rating in a research note on Monday, June 12th. Zacks Investment Research cut Flexion Therapeutics from a hold rating to a sell rating in a research note on Thursday, July 13th. ValuEngine raised Flexion Therapeutics from a sell rating to a hold rating in a research note on Wednesday, June 21st. Finally, Janney Montgomery Scott reaffirmed a buy rating and set a $35.00 target price (up previously from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics has an average rating of Buy and a consensus price target of $88.50.

Shares of Flexion Therapeutics (FLXN) opened at 26.21 on Monday. The firm has a 50-day moving average price of $25.08 and a 200 day moving average price of $22.65. Flexion Therapeutics has a 12-month low of $15.93 and a 12-month high of $32.25. The stock’s market cap is $836.23 million.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). Equities research analysts expect that Flexion Therapeutics will post ($3.78) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Needham & Company LLC Boosts Flexion Therapeutics, Inc. (FLXN) Price Target to $42.00” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/12/needham-company-llc-boosts-flexion-therapeutics-inc-flxn-price-target-to-42-00.html.

In other news, insider Yamo Deniz acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were bought at an average price of $24.15 per share, with a total value of $72,450.00. Following the completion of the purchase, the insider now directly owns 5,000 shares in the company, valued at $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders purchased 5,375 shares of company stock worth $131,575. 15.98% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in FLXN. Bank of New York Mellon Corp grew its stake in Flexion Therapeutics by 27.9% in the second quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after purchasing an additional 591,981 shares in the last quarter. State Street Corp grew its stake in Flexion Therapeutics by 66.3% in the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock worth $27,888,000 after purchasing an additional 549,948 shares in the last quarter. Wasatch Advisors Inc. grew its stake in Flexion Therapeutics by 58.7% in the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after purchasing an additional 376,745 shares in the last quarter. Nexthera Capital LP bought a new position in Flexion Therapeutics in the second quarter worth approximately $4,661,000. Finally, Pictet Asset Management Ltd. grew its stake in Flexion Therapeutics by 73.7% in the second quarter. Pictet Asset Management Ltd. now owns 472,796 shares of the specialty pharmaceutical company’s stock worth $8,080,000 after purchasing an additional 200,657 shares in the last quarter. 83.26% of the stock is currently owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.